BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 6255862)

  • 1. Synergistic activity of piperacillin in combination with beta-lactamase inhibitors.
    Neu HC; Fu KP
    Antimicrob Agents Chemother; 1980 Oct; 18(4):582-5. PubMed ID: 6255862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative in vitro and in vivo activities of piperacillin combined with the beta-lactamase inhibitors tazobactam, clavulanic acid, and sulbactam.
    Kuck NA; Jacobus NV; Petersen PJ; Weiss WJ; Testa RT
    Antimicrob Agents Chemother; 1989 Nov; 33(11):1964-9. PubMed ID: 2558615
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Susceptibility of clinical isolates to expanded-spectrum beta-lactams alone and in the presence of beta-lactamase inhibitors.
    Qadri SM; Ueno Y; Cunha BA
    Chemotherapy; 1996; 42(5):334-42. PubMed ID: 8874972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative in vitro activities of piperacillin-tazobactam and ticarcillin-clavulanate.
    Fass RJ; Prior RB
    Antimicrob Agents Chemother; 1989 Aug; 33(8):1268-74. PubMed ID: 2552904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In-vitro evaluation of the four beta-lactamase inhibitors: BRL42715, clavulanic acid, sulbactam, and tazobactam.
    Muratani T; Yokota E; Nakane T; Inoue E; Mitsuhashi S
    J Antimicrob Chemother; 1993 Sep; 32(3):421-9. PubMed ID: 8262864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activities of the beta-lactamase inhibitors clavulanic acid, sulbactam, and tazobactam alone or in combination with beta-lactams against epidemiologically characterized multidrug-resistant Acinetobacter baumannii strains.
    Higgins PG; Wisplinghoff H; Stefanik D; Seifert H
    Antimicrob Agents Chemother; 2004 May; 48(5):1586-92. PubMed ID: 15105109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic activity of mecillinam in combination with the beta-lactamase inhibitors clavulanic acid and sulbactam.
    Neu HC
    Antimicrob Agents Chemother; 1982 Sep; 22(3):518-9. PubMed ID: 6291454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bacteriological investigations with beta-lactamase inhibitors.
    Ullmann U
    Zentralbl Bakteriol Mikrobiol Hyg A Med Mikrobiol Infekt Parasitol; 1982 Jun; 252(2):222-9. PubMed ID: 6289565
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative activities of the beta-lactamase inhibitors YTR 830, clavulanate, and sulbactam combined with ampicillin and broad-spectrum penicillins against defined beta-lactamase-producing aerobic gram-negative bacilli.
    Jacobs MR; Aronoff SC; Johenning S; Shlaes DM; Yamabe S
    Antimicrob Agents Chemother; 1986 Jun; 29(6):980-5. PubMed ID: 3015017
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic activity of cefoperazone in combination with beta-lactamase inhibitors.
    Fu KP; Neu HC
    J Antimicrob Chemother; 1981 Mar; 7(3):287-92. PubMed ID: 6268598
    [No Abstract]   [Full Text] [Related]  

  • 11. Comparative evaluation of the in vitro activity of three combinations of beta-lactams with beta-lactamase inhibitors: piperacillin/tazobactam, ticarcillin/clavulanic acid and ampicillin/sulbactam.
    Sader HS; Tosin I; Sejas L; Miranda E
    Braz J Infect Dis; 2000 Feb; 4(1):22-8. PubMed ID: 10788842
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clavulanic acid and CP-45,899: a comparison of their in vitro activity in combination with penicillins.
    Wise R; Andrews JM; Bedford KA
    J Antimicrob Chemother; 1980 Mar; 6(2):197-206. PubMed ID: 6247316
    [No Abstract]   [Full Text] [Related]  

  • 13. Tazobactam is a potent inactivator of selected inhibitor-resistant class A beta-lactamases.
    Bonomo RA; Rudin SA; Shlaes DM
    FEMS Microbiol Lett; 1997 Mar; 148(1):59-62. PubMed ID: 9066111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of beta-lactamases by tazobactam and in-vitro antibacterial activity of tazobactam combined with piperacillin.
    Higashitani F; Hyodo A; Ishida N; Inoue M; Mitsuhashi S
    J Antimicrob Chemother; 1990 Apr; 25(4):567-74. PubMed ID: 2161820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Variation in the potentiation of beta-lactam antibiotic activity by clavulanic acid and sulbactam against multiply antibiotic-resistant bacteria.
    Aldridge KE; Sanders CV; Marier RL
    J Antimicrob Chemother; 1986 Apr; 17(4):463-9. PubMed ID: 3011724
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beta-lactamase inhibition by acetylmethylene penicillanic acid compared to that of clavulanate and sulbactam.
    Chin NX; McElrath MJ; Neu HC
    Chemotherapy; 1988; 34(4):318-25. PubMed ID: 2850139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation of the effect of beta-lactamase inhibitors on the beta-lactamase in growing cultures of gram-negative bacteria with their effect on the isolated beta-lactamase.
    Easton CJ; Knowles JR
    Antimicrob Agents Chemother; 1984 Sep; 26(3):358-63. PubMed ID: 6095753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro antimicrobial activity of piperacillin/tazobactam in comparison with other broad-spectrum beta-lactams.
    Roland RK; Mendes RE; Silbert S; Bolsoni AP; Sader HS
    Braz J Infect Dis; 2000 Oct; 4(5):226-35. PubMed ID: 11063554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative activities of the beta-lactamase inhibitors YTR 830, clavulanate and sulbactam combined with extended-spectrum penicillins against ticarcillin-resistant Enterobacteriaceae and pseudomonads.
    Jacobs MR; Aronoff SC; Johenning S; Yamabe S
    J Antimicrob Chemother; 1986 Aug; 18(2):177-84. PubMed ID: 3019984
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative in vitro activity of piperacillin combined with the beta-lactamase inhibitor tazobactam (YTR 830).
    Eliopoulos GM; Klimm K; Ferraro MJ; Jacoby GA; Moellering RC
    Diagn Microbiol Infect Dis; 1989; 12(6):481-8. PubMed ID: 2560420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.